Table 3.

Trial schedule.

Visit action	Screening	Visit 1	Visit 2	Visit 3	Visit 4
Trial day	Day −28 to 1	Day 1	Day 28 ± 5	Day 35−1/+3	Day 63 ± 5
Demographics (sex, age)	x
Patient information and informed consent	X
Previous and concomitant diseases	X
Previous and concomitant treatments	X
Inclusion/exclusion criteria	X
Vital signs (blood pressure, pulse)	X		X		X
Best-corrected visual acuity	X	X	X	X	X
Pregnancy test (if woman of childbearing potential)	X
Laboratory tests	X		X		X
IOP (8.00, 12.00, and 16.00 ± 1 h)	X	X	X	X	X
Application of study medication by study personnel (16 : 00 ± 1 h, after IOP measurement)		X		X
Randomization		X
Slit-lamp examination	X	X	X	X	X
Dilated fundus examination	X				X
Dispensation of study medication		X		X
Symptom survey			X		X
Changes in medical health or concomitant medication		X	X	X	X
Adverse events		X	X	X	X
End of trial (final visit)					X